Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, a clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19. The company was founded in 2014 and is headquartered in Wilmette, Illinois. Show more
1000 Skokie Boulevard, Wilmette, IL, 60091, United States
Start AI Chat
Market Cap
372.9M
52 Wk Range
$26.05 - $105.00
Previous Close
$55.80
Open
$56.29
Volume
352,702
Day Range
$55.88 - $61.30
Enterprise Value
546.6M
Cash
143.7M
Avg Qtr Burn
-2.091M
Insider Ownership
23.72%
Institutional Own.
82.83%
Qtr Updated
09/30/25
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
ALXN1840 (tiomolybdate choline) Details Wilson disease | NDA Submission | |
MNPR-101-Zr Details Cancer, Solid tumor/s | Phase 1 Update | |
MNPR-101-RIT Details Cancer | Phase 1 Update | |
MNPR-101-Lu Details Cancer | Phase 1a Data readout |
